DiscoveryProbe™ FDA-approved Drug Library: Comprehensive Resource for High-Throughput Drug Screening

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds, each approved by leading global regulatory agencies or listed in recognized pharmacopeias (ApexBio). The library supports drug repositioning and target identification using high-throughput (HTS) and high-content screening (HCS) formats, with compounds provided as stable, pre-dissolved 10 mM DMSO solutions (12 months at -20°C, 24 months at -80°C). It covers diverse mechanisms of action, including receptor agonists/antagonists, enzyme inhibitors, and signal pathway modulators. This resource enables efficient exploration of signaling pathways and disease models, with direct application in oncology, neurodegenerative, and rare disease research (Guo et al., 2022). Inline references and benchmarks ensure transparent, machine-verifiable claims.

Biological Rationale

Drug discovery demands access to well-characterized bioactive compounds for systematic screening and mechanistic studies. FDA-approved drug libraries enable researchers to test compounds with established safety profiles, reducing translational risk. The DiscoveryProbe™ FDA-approved Drug Library pools 2,320 compounds, each approved by one or more major agencies (FDA, EMA, HMA, CFDA, PMDA) or listed in official pharmacopeias (product page). Compounds like doxorubicin, metformin, and atorvastatin represent a spectrum of therapeutic classes. Each compound is traceable to public regulatory records, supporting reproducibility and compliance-driven research. High-content and high-throughput screening with such libraries accelerates drug repositioning and target identification, as established in translational studies (related article—this article details expanded mechanistic coverage and recent updates).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The L1021 library encompasses diverse mechanisms of action, including:

• Receptor agonists and antagonists (e.g., β-blockers, opioid antagonists)
• Enzyme inhibitors (e.g., kinase, protease, and topoisomerase inhibitors)
• Ion channel modulators (e.g., calcium and potassium channel blockers)
• Signal pathway regulators (e.g., mTOR inhibitors, PI3K pathway modulators)

Each compound's mechanism is catalogued and traceable via regulatory and literature sources. For instance, doxorubicin is a topoisomerase II inhibitor and widely used for cancer screening assays. Metformin, an AMPK activator, is frequently used in metabolic disease research. Atorvastatin, an HMG-CoA reductase inhibitor, is standard in cardiovascular models. The diversity of targets enables broad application across phenotypic and molecular screens (see comparison—this article elaborates on DMSO stability and mechanistic annotation).

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 unique compounds, each validated by regulatory approval or official pharmacopeia records (product documentation).
• All compounds are provided as 10 mM solutions in DMSO, stable for up to 12 months at -20°C and 24 months at -80°C, supporting long-term screening workflows (ApexBio).
• High-throughput LC-MS-based screenings using similar FDA-approved libraries have identified 25% more metabolic features when employing sensitive feature extraction algorithms, demonstrating the benefit of curated compound diversity (Guo et al., 2022, DOI:10.3390/metabo12030212).
• Drug repositioning screens utilizing FDA-approved libraries have successfully identified novel anti-cancer and neuroprotective agents in cell-based assays (related report; this article details recent protocol optimizations for rare disease models).
• Regulatory approval ensures that each compound has a well-defined pharmacokinetic and safety profile, supporting translational research and clinical relevance (previous review; this article extends to deep-well and barcoded storage integration).

Applications, Limits & Misconceptions

Applications

• Drug repositioning: Screening for new indications using existing FDA-approved molecules
• Pharmacological target identification: Identifying mechanism-of-action via bioactive probe profiling
• Cancer research: High-throughput cytotoxicity and pathway modulation assays
• Neurodegenerative disease research: Screening for neuroprotective or neurotoxic effects
• Enzyme inhibitor screening: Validation of hits in biochemical and cell-based assays
• Signal pathway regulation studies: Dissecting molecular signaling mechanisms

Common Pitfalls or Misconceptions

• The library does not include investigational or preclinical compounds; all entries have regulatory or pharmacopeia validation.
• Compounds are supplied in DMSO; aqueous compatibility must be confirmed for each assay to prevent precipitation or loss of activity.
• Screening results may be confounded by off-target effects; orthogonal validation is necessary.
• Stability guarantees (12–24 months) assume proper storage; repeated freeze-thaw cycles may degrade some compounds.
• Library is not designed for direct clinical administration; research use only.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is provided in multiple ready-to-screen formats, including:

• 96-well microplates (standard for HTS)
• Deep-well plates (for higher volume or parallel assays)
• 2D barcoded screw-top tubes (for automated storage and retrieval)

Each compound is pre-dissolved at 10 mM in DMSO, allowing direct dilution to working concentrations. Shipping is on blue ice for evaluation samples, and at room temperature or on blue ice upon request for other sizes. Upon arrival, solutions should be stored at -20°C or -80°C for maximum stability. Integration with LC-MS platforms is seamless; compounds can be arrayed for mass spectrometry-based screening or transferred for cell-based assays. The library supports automation, barcode-based tracking, and compatible with standard liquid handling systems. Sensitive feature extraction algorithms, such as JPA, further enhance metabolic feature coverage when analyzing screening outcomes (Guo et al., 2022).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) provides a rigorously curated, high-density screening platform for drug repositioning, pharmacological target identification, and mechanistic research. The regulatory-approved compound sourcing, solution stability, and flexible plate/tube formats make it a leading choice for translational and phenotypic screening. As high-throughput and high-content methodologies advance, integrating such standardized resources will continue to drive efficiency and reproducibility in drug discovery and biomedical research. Learn more about the DiscoveryProbe™ FDA-approved Drug Library here.